Tag: HiPoint reperfusion system
Route 92 announces first commercial cases in Canada
Route 92 Medical has announced its first commercial cases in Canada following receipt of a Health Canada medical device licence for the company’s portfolio...
Route 92 Medical announces US$50 million in growth financing
Route 92 Medical has announced today that it has raised US$50 million in growth financing. New investor Sectoral Asset Management joined lead investor Novo...
Route 92 begins enrolment in SUMMIT RISE study evaluating company’s stroke...
Route 92 Medical has today announced the first enrolment in SUMMIT RISE—a 500-patient, real-world, post-clearance study evaluating the performance of the company’s portfolio of...
HiPoint Reperfusion System is “pushing the boundaries” of stroke thrombectomy treatments
In light of the recently presented and overwhelmingly positive findings of the SUMMIT MAX randomised controlled trial (RCT), leading study investigator Ajit Puri (Worcester,...
Interventional stroke care set for paradigm shift following “phenomenal success” of...
This advertorial is sponsored by Route 92 Medical.
Following the recent US Food and Drug Administration (FDA) clearance of the HiPoint Reperfusion System (Route 92...
Route 92 announces new data on HiPoint reperfusion system alongside SUMMIT...
Route 92 Medical has today announced results from an independent, real-world study evaluating reperfusion outcomes following use of the company’s HiPoint reperfusion system—described by...
